Pharmaceutical

ImmunoPrecise announced the engagement of TerraMar Environmental Research to develop immune-contraceptive vaccines for overabundant wildlife populations.

ImmunoPrecise (TSXV:IPA) announced the engagement of TerraMar Environmental Research to develop immune-contraceptive vaccines for overabundant wildlife populations.
As quoted in the press release:

TerraMar is a privately held, environmental research consultancy based in Sidney, British Columbia.  Mark Fraker, PhD, Principal at TerraMar, has been working on development of immune-contraceptive vaccines for the past two decades.  The first opportunity the Company will pursue is to complete development of a vaccine that has been previously tested in feral and wild overabundant animal populations.  The lead candidate will target large-animal, overabundant animal populations such as deer, Asian elephants, wild camels, wild burros and wild horses.  The Company will specifically be engaging TerraMar to assist in executing the vaccine development plan and working with Regulatory agencies for approval throughout the world.
“Using immuno-contraception is far more humane and cost effective than surgical procedures or killing animals to control their populations,” said Mark Fraker. “There are significant populations of feral and wild animals in various parts of the world that crowd out indigenous species, become vectors for dangerous diseases or cause physical damage to their environment when their populations are out of control.  The economic cost of overabundant animal population is considerable.”

Click here to read the full press release.

Source: www.newswire.ca

Featured

MARKETS

Markets
TSX20274.54+76.93
TSXV699.25-2.84
DOW31626.26-253.98
S&P 5003909.62-64.13
NASD11216.40-318.87
ASX7148.90+3.30

COMMODITIES

Commodities
Gold1869.29+15.62
Silver22.12+0.38
Copper4.30-0.04
Palladium2009.00+24.00
Platinum960.50+7.50
Oil109.52-0.77
Heating Oil3.640.00
Natural Gas8.740.00

DOWNLOAD FREE REPORTS

×